Clinical trials recruiting for Anatomic Stage II Breast Cancer AJCC v8
35
Recruiting trials
51
US states with sites
3
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Cyclophosphamide | 4 |
| Paclitaxel | 4 |
| Pembrolizumab | 4 |
| Carboplatin | 3 |
| Docetaxel | 3 |
| Doxorubicin | 3 |
| Pertuzumab | 3 |
| Fisetin | 2 |
| Trastuzumab | 2 |
| Abemaciclib | 1 |
| Anastrozole | 1 |
| Aromatase Inhibition Therapy | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 12 |
| Florida | 9 |
| Ohio | 9 |
| Arizona | 6 |
| Minnesota | 6 |
| Connecticut | 5 |
| Georgia | 5 |
| Michigan | 5 |
| New Jersey | 5 |
| New York | 5 |
| North Carolina | 5 |
| Pennsylvania | 5 |
Top cities
Columbus, Ohio 9Duarte, California 7Beverly Hills, California 6Irvine, California 6Jacksonville, Florida 6Los Angeles, California 6Atlanta, Georgia 5Houston, Texas 5Pasadena, California 5Seattle, Washington 5
Self-screener
Recruiting trials
- 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
- A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
- A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors
- Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Breast Cancer Survivorship Biorepository
- Breast Cancer, Reasoning, and Activity Intervention
- Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
- Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
- DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
- Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
- Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
- Evaluating the Association Among Changes in Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer
- Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients
- Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
- Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
- Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
- Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
- Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
- Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer
- Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
- Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
- Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
- Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial
- Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
- Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
- Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
- Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial
- ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
- The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients
- Time Restricted Eating for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery
- Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer
- Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
Related conditions
Trials recruiting for Anatomic Stage II Breast Cancer AJCC v8 often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239Anatomic Stage I Breast Cancer AJCC v8 30Anatomic Stage III Breast Cancer AJCC v8 39Anatomic Stage IIIA Breast Cancer AJCC v8 10HER2 Negative Breast Carcinoma 15Anatomic Stage IV Breast Cancer AJCC v8 43Triple-Negative Breast Carcinoma 10Invasive Breast Carcinoma 14Hormone Receptor Positive Breast Carcinoma 13Breast Carcinoma 74
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Anatomic Stage II Breast Cancer AJCC v8 trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.